NVAX · Novavax, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on NVAX. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About NVAX · Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Live Quote
HOLD (score +1) · 12-1 mom 38.4% · RSI 46.4 · above_200_only · -19.6% from high
Targets blend Wall Street consensus (9 analysts: low $7.00 / mean $14.11 / high $25.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Novavax has completed its strategic pivot from direct COVID-19 vaccine sales to a licensing/adjuvent model following the Sanofi (Europe handoff) and Pfizer ($30M upfront + up to $500M milestones for Matrix-M in two disease fields) deals. Q1 2026 results beat on partnership-driven revenue ($139.5M), but the company remains unprofitable with deeply negative forward P/E. The stock is 24.8% off its recent peak near $11.19 (Feb 26, 2026) and has drifted below its 50-DMA into consolidation. All insider Form 4s reviewed are RSU vesting events — no open-market purchases by executives. The Aug 5 earnings represents the next key catalyst. Options flow shows heavy OI concentration in OTM $12 calls (283 contracts), suggesting bull-side speculative positioning, but IV data is unreliable (null bid/ask across most strikes).